Report: Medical marijuana could poach more than $4B from pharma sales annually

The report is intended to show how cannabis could disrupt pharmaceutical sales in key treatment areas including chronic pain, PTSD, sleep disorders, anxiety, epilepsy, and chemotherapy side effects.

If the United States legalized medical marijuana for conditions such as chronic pain, anxiety and seizures, cannabis could siphon more than $4 billion annually from the nation’s pharmaceutical industry, a new study hypothesizes.

The report expected to be released Wednesday by New Frontier Data, a provider of data and analytics to cannabis businesses, is intended to show how cannabis could disrupt pharmaceutical sales in nine key treatment areas.

“Any opportunity for alternatives that could result in reduced pharmaceutical drug use might present a compelling point of discussion from a public policy standpoint,” said John Kagia, executive vice president of industry analytics for the Washington, D.C.-based New Frontier.

Read More at TheCannabist.co